CMHC Accreditation
Activity Title:
13th Annual Cardiometabolic Health Congress
Activity Date:
October 24-27, 2018 | Boston, Massachusetts
Target Audience
The CMHC is designed for advanced level clinicians responsible for the prevention, diagnosis, and management of cardiometabolic risk including cardiologists, endocrinologists, diabetologists, lipidologists, pharmacists, primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), and other allied health professionals.
Statement of Need/Program Overview
The ever-increasing presence of cardiometabolic risk continues to be a major challenge for health care providers in the United States. Current estimates suggest approximately 23% - 38% of all U.S. adults have metabolic syndrome, a constellation of cardiometabolic risk factors, including excessive abdominal fat, insulin resistance, inflammation, dyslipidemia, and hypertension. Patients with multiple cardiometabolic risk factors have twice the likelihood of developing and dying from cardiovascular disease and more than seven times the risk of developing diabetes compared to those with no cardiometabolic risk factors. Cardiovascular disease currently affects approximately 83.6 million U.S. adults (> 1 in 3) and is the leading cause of U.S. deaths; however, this CVD burden is expected to increase.
This sampling of sobering statistics points to a rapidly growing epidemic of cardiovascular and metabolic disease and calls to the forefront the need for medical education focused on all aspects of cardiometabolic risk. The Cardiometabolic Health Congress (CMHC) presents an especially valuable venue for this educational outreach bringing together faculty members from multiple disciplines, including cardiology, endocrinology, and primary care, to lead sessions that foster a collaborative, multidisciplinary approach to care.
The 2018 CMHC will translate the latest cutting edge medical research into practical, clinical strategies for preventing, delaying, diagnosing, treating, and managing cardiovascular and metabolic disorders. The goal is to provide the medical community with evidence based interventions that they can apply immediately in clinical practice to improve health outcomes and quality of life for the growing numbers of patients at increased cardiometabolic risk.
Educational Objectives
After completing this activity, the participant should be better able to:
Faculty
Please click here to view all faculty listings.
Program Agenda
Please click here to view the full agenda.
SCOPE Certification
The World Obesity/Clinical Care committee decided that the further learning value, quality and structure of the 13th Annual Cardiometabolic Health Congress comply with Specialist Certification of Obesity Professional Education (SCOPE) principles. This event has been accredited with 4 SCOPE Points which count towards SCOPE Certification.
SCOPE Certification is conferred by the World Obesity Federation and is the internationally-recognized standard of excellence in obesity management. SCOPE Certification is awarded to health professionals with obesity management experience who have earned 12 SCOPE points.
For questions regarding SCOPE points, please contact info@cardiometabolichealth.org.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and CMHC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this live activity for a maximum of 21.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 21.75 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacotherapy hours will be included in this activity. Hours are listed below.
Session Title |
Pharmacotherapy Hours |
Pre-Conference |
|
Cardio-oncology: Overview and the Intersection Between Breast Cancer and Cardiovascular Disease |
0.2 |
Cardiometabolic Risk in PCOS and Implications for Management |
0.1 |
Impact of Pregnancy on CV Risk Factors and ASCVD Risk |
0 |
Choosing Wisely: Contraception in Women with Cardiometabolic Risk |
0.3 |
Updates on the Role of Postmenopausal Hormone Replacement Therapy/Women's Health Summit Expert Panel Discussion and Q&A |
0.3 |
Session I: Diabetes Management |
|
FDA Update and Late Breaking Trials |
0.9 |
Keynote |
0.2 |
Workshop: Insulin Biosimilars |
0.6 |
So Many Options - Dispelling the Confusion About Insulins |
0.6 |
Where are we with Devices for Diabetes Management? |
0 |
How Many GLP-1 RAs Do We Need and Why? |
0.6 |
Multidisciplinary Case Consults in Diabetes Management |
0.5 |
Workshop: Real-world Digital Health Implementations to Improve Blood Pressure Control |
0 |
Session II: Obesity and Lifestyle Management in Cardiovascular Disease |
|
Interventional Cardiology Delivered with a Fork |
0 |
Updates on Metabolic Surgery |
0.1 |
Obesity and Environmental Influence: The Big Picture |
0 |
Workshop: Prevent Type 2 Diabetes with Digital Health: Effective and Realistic Solutions |
0 |
Day to Day Management of Obesity in Clinical Practice |
0.2 |
Session III: Dyslipidemia, Atherosclerosis, and Cardiovascular Disease Risk Reduction |
|
Targeting Inflammation: Updates on Pathophysiology and Clinical Outcomes |
0.4 |
How Aggressively do we Lower LDL-C and for Which Patients? |
0.9 |
Workshop: Don't Hit the Snooze Button on Sleep: The Role of Sleep in Cardiometabolic Health |
0 |
Risk Assessment for Global Cardiovascular Disease: Imaging and Biomarkers |
0.2 |
Multidisciplinary Case Consults in Lipid Disorders |
0.4 |
Session IV: Hypertension, Cardio-renal, and Heart Failure |
|
Overview of the New 2017 Hypertension Clinical Practice Guidelines |
0.5 |
Comparing the Hypertension Guidelines - Where is the Equipoise? |
0.4 |
Patient Cases: How would you change the management of hypertension based on the new guidelines? |
0.2 |
Prevention of Heart Failure: The Next Frontier |
0.2 |
Integration of Biomarkers and Prediction of AKI and Cardio-renal Outcomes in Clinical Practice |
0.1 |
AKI and Heart Failure: How to manage compared to general population? |
0.2 |
Advanced CKD and Benefits from CVOTs |
0.5 |
Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credit Designation
Global Education Group designates this continuing education activity for 21.75 contact hour(s) (2.175 CEUs) of the Accreditation Council for Pharmacy Education. This is a knowledge based activity. Universal Activity Numbers (UAN) are listed below.
Session Title |
UAN |
Pre-Conference |
|
Cardio-oncology: Overview and the Intersection Between Breast Cancer and Cardiovascular Disease |
0530-9999-18-334-L01-P |
Cardiometabolic Risk in PCOS and Implications for Management |
0530-9999-18-335-L01-P |
Impact of Pregnancy on CV Risk Factors and ASCVD Risk |
0530-9999-18-336-L01-P |
Choosing Wisely: Contraception in Women with Cardiometabolic Risk |
0530-9999-18-337-L01-P |
Updates on the Role of Postmenopausal Hormone Replacement Therapy/Women's Health Summit Expert Panel Discussion and Q&A |
0530-9999-18-338-L01-P |
Session I: Diabetes Management |
|
FDA Update and Late Breaking Trials |
0530-9999-18-341-L01-P |
Keynote |
0530-9999-18-342-L01-P |
Workshop: Insulin Biosimilars |
0530-9999-18-343-L01-P |
So Many Options - Dispelling the Confusion About Insulins |
0530-9999-18-344-L01-P |
Where are we with Devices for Diabetes Management? |
0530-9999-18-347-L01-P |
How Many GLP-1 RAs Do We Need and Why? |
0530-9999-18-348-L01-P |
Multidisciplinary Case Consults in Diabetes Management |
0530-9999-18-349-L01-P |
Workshop: Real-world Digital Health Implementations to Improve Blood Pressure Control |
0530-9999-18-350-L01-P |
Session II: Obesity and Lifestyle Management in Cardiovascular Disease |
|
Interventional Cardiology Delivered with a Fork |
0530-9999-18-354-L01-P |
Updates on the Microbiome and Metabolic Surgery |
0530-9999-18-355-L01-P |
Obesity and Environmental Influence: The Big Picture |
0530-9999-18-356-L01-P |
Workshop: Prevent Type 2 Diabetes with Digital Health: Effective and Realistic Solutions |
0530-9999-18-357-L01-P |
Day to Day Management of Obesity in Clinical Practice |
0530-9999-18-358-L01-P |
Session III: Dyslipidemia, Atherosclerosis, and Cardiovascular Disease Risk Reduction |
|
Targeting Inflammation: Updates on Pathophysiology and Clinical Outcomes |
0530-9999-18-361-L01-P |
How Aggressively do we Lower LDL-C and for Which Patients? |
0530-9999-18-362-L01-P |
Workshop: Don't Hit the Snooze Button on Sleep: The Role of Sleep in Cardiometabolic Health |
0530-9999-18-363-L01-P |
Risk Assessment for Global Cardiovascular Disease: Imaging and Biomarkers |
0530-9999-18-364-L01-P |
Multidisciplinary Case Consults in Lipid Disorders |
0530-9999-18-365-L01-P |
Session IV: Hypertension, Cardio-renal, and Heart Failure |
|
Overview of the New 2017 Hypertension Clinical Practice Guidelines |
0530-9999-18-367-L01-P |
Comparing the Hypertension Guidelines - Where is the Equipoise? |
0530-9999-18-368-L01-P |
Patient Cases: How would you change the management of hypertension based on the new guidelines? |
0530-9999-18-369-L01-P |
Prevention of Heart Failure: The Next Frontier |
0530-9999-18-370-L01-P |
Integration of Biomarkers and Prediction of AKI and Cardio-renal Outcomes in Clinical Practice |
0530-9999-18-371-L01-P |
AKI and Heart Failure: How to manage compared to general population? |
0530-9999-18-372-L01-P |
Advanced CKD and Benefits from CVOTs |
0530-9999-18-373-L01-P |
Dietician Accreditation Statement
Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 21.75 Continuing Professional Education units (CPEUs) for completion of this activities / materials.
CPE Provider #GE012
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Instructions to Receive Credit
Learners may earn 21.75 credit hours by attending all Pre-Conference Sessions, General Sessions, and Workshops* and an additional 7.5 credit hours by attending a maximum of 6 CME Satellite Symposia; maximum credit hours possible is 29.25. *Registration is required for Workshops and seating is limited. Click here for the full symposia listing and credit hour information.
If attending a CME Satellite Symposium, individual symposium evaluations are available to complete via the CMHC Mobile app, or by visiting https://eventmobi.com/cmhc2018/ and clicking on “CME Symposia Evaluations” under the Menu.
For the overall conference evaluation, all attendees will be emailed the CMHC Online Evaluation link by Monday, October 29, 2018. The evaluation will request that you check off which sessions (Pre-Conference, General Sessions, Workshops, and CME Symposia) you have attended. The evaluation must be completed by November 19, 2018. CME/CE Certificates will be available for print immediately upon completion of the online evaluation form. Reminder emails will be sent each evening as well. Please continue to check this page for updates as credit hours may change. For any questions please contact info@cardiometabolichealth.org.
Pharmacists Only: In order to receive credit, the ACPE requires that you provide your NABP ePID (6-10 digits) along with month and date of birth (MM/DD) in the online evaluation. After completion of the evaluation via steps outlined above, record of your participation will be uploaded to the CPE Monitor under your NABP e-profile within 60 days. You may print an individual statement of credit for this activity from your NABP e-profile. CMHC strongly encourages you to check your e-profile to ensure your credit is appropriately claimed before December 23, 2018.
Fee Information & Refund/Cancellation Policy
There is a registration fee for this educational activity, registration information can be found here.
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner or Manager |
Reported Financial Relationship |
Ashley Marostica, RN, MSN |
Nothing to disclose |
Lindsay Borvansky |
Nothing to disclose |
Andrea Funk |
Nothing to disclose |
Amanda Turner |
Nothing to disclose |
Liddy Knight |
Nothing to disclose |
Erin Franceschini, MS |
Nothing to disclose |
Amanda Jamrogiewicz |
Nothing to disclose |
Karin McAdams |
Nothing to disclose |
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and CMHC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Educational Grant Support
The 13th Annual CMHC is supported in part by an independent and unrestricted educational grant from Akcea Therapeutics, Amarin Pharma Inc., Novartis Pharmaceuticals Corporation, and Novo Nordisk. Please continue to check this page for updates.
For educational symposia support information, including accreditation, please visit this page.
This activity is jointly provided by Global Education Group and Tarsus Cardio Inc. dba Cardiometabolic Health Congress.